Fig. 8

Silencing METTL3 mitigates AD pathology in APP/PS1 mice. AAV containing shMETTL3 or control (shControl) was injected into the bilateral hippocampi of 5-month-old APP/PS1 mice. Two weeks later, the mice underwent NOR and MWM, and were sacrificed for WB and qRT-PCR analyses. a, b Performance in MWM. Latency during the learning stage was recorded (a). The representative traces (a) and crossing times (b) on day 7 were analyzed (n = 8). The experimental groups were as follows: W—WT mice injected with shControl AAV, A—APP/PS1 mice injected with shControl AAV, S—APP/PS1 mice injected with shMETTL3 AAV. Statistical analysis was performed using one-way ANOVA with LSD post-hoc test for (b). c Recognition memory was tested by NOR. Statistical analysis was performed using one-way ANOVA with LSD post-hoc test. d WB for METTL3, GluN2B, SYN1, and PSD95 in hippocampal homogenates (left) and quantitative analysis (right) (n = 3). e qRT-PCR analysis was performed to detect circRIMS2 (n = 3). Data are presented as mean ± SEM and two-tailed t tests were used unless otherwise specified. *P < 0.05, **P < 0.01 vs W; ^#P < 0.05, ^##P < 0.01 vs A